Aspirin Resistance in Cardiovascular Disease: A Review of Prevalence, Mechanisms, and Clinical Significance

Keywords

Aspirin - aspirin resistance - platelet function - antiplatelet therapy

• References

• 1 Jack DB. One hundred years of aspirin. Lancet 1997; 350: 437-9.
• 2 de Gaetano G. Historical overview of the role of platelets in hemostasis and thrombosis. Haematologica 2000; 85: 3-10.
• 3 Vane JR. Inhibition of prostaglandin syntheses as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-5.
• 4 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci 1975; 72: 2994-8.
• 5 Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci 1975; 72: 3073-6.
• 6 Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. J Clin Invest 1975; 56: 624-32.
• 7 Rome LH, Lands WEM. Aspirin as a quantitative acetylating reagent for the fatty acid oxygenase that forms prostaglandins. Prostaglandins 1976; 11: 23-30.
• 8 Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978; 61: 314-9.
• 9 Burch JW, Baenziger NL, Stanford N, Majerus PW. Sensitivity of fatty acid cyclooxygenase from human aorta to acetylation by aspirin. Proc Natl Acad Sci 1978; 75: 5181-4.
• 10 Baenziger NL, Becherer PR, Majerus PW. Characterization of prostacyclin synthesis in cultured human arterial smooth muscle cells, venous endothelial cells and skin fibroblasts. Cell 1979; 16: 967-74.
• 11 Majerus PW. Arachidonate metabolism in vascular disorders. J Clin Invest 1983; 72: 1521-5.
• 12 Picot D, Loll PJ, Garavito RM. The X-ray crystal structure of the membrane protein prostaglandin H₂ synthase-1. Nature 1994; 367: 243-9.
• 13 Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H₂ synthase. Nat Struct Biol 1995; 02 (08) 637-43.
• 14 Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
• 15 Second International Study of Infarct Survival Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 02: 349-60.
• 16 Steering Committee of the Physicians’ Health Study Research Group. Preliminary report: findings from the aspirin component of the ongoing physician’s health study. N Engl J Med 1988; 318: 262-4.
• 17 Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing physicians’ health study. N Engl J Med 1989; 321: 129-35.
• 18 Metha J, Metha P, Burger C, Pepine CJ. Platelet aggregation studies in coronary artery disease. Atherosclerosis 1978; 31: 169-75.
• 19 Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: Implications for the use of ASA clinically. Can J Cardiol 1995; 11: 221-7.
• 20 Hurlen M, Seljeflot I, Arnesen H. The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction. Scand Cardiovasc J 1988; 32: 233-7.
• 21 Pappas JM, Westengard JC, Bull BS. Population variability in the effect of aspirin on platelet function. Arch Pathol Lab Med 1994; 118: 801-4.
• 22 Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients; evidence of nonresponders in a subpopulation of treated patients. Thromb Res 1991; 63: 587-93.
• 23 Grotemeyer KH. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993; 71: 397-403.
• 24 Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, Koppensteiner R, Ergun E, Mittleboeck M, Schreiner W, Losert U, Wolner E. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78: 1003-7.
• 25 Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers JW, Simoons ML, Guerci A, Hochman JS, Wilcox RG, Kitt MM, Eisenberg PR, Califf RM, Topol EJ, Karsh K, Ruzyllo W, Stepinska J, Widimsky P, Boland JB, Armstrong PW. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. Am J Cardiol 1999; 83: 1147-51.
• 26 Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirinresistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5.
• 27 Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-5.
• 28 Nicholson NS, Panzer-Knodle SG, Haas NF, Taite BB, Szalony JA, Page JD, Feigen LP, Lansky DM, Salyers AK. Assessment of platelet function assays. Am Heart J 1998; 135: S170-8.
• 29 Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100®. Thromb Haemost 2000; 83: 316-21.
• 30 Hung J, Lam JYT, Lacoste L, Letchavobski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92: 2432-6.
• 31 Livio M, Del Maschio A, Cerletti C, de Gaetano G. Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclooxygenase activity. Prostaglandins 1982; 23 (06) 787-96.
• 32 Rao GHR, Johnson GG, Reddy KR, White JG. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis 1983; 03: 383-8.
• 33 Loll P, Picot D, Ekabo O, Garavito RM. Synthesis and use of iodinated nonsteroidal anti-inflammatory drug analogs as crystallographic probes of the prostaglandin H₂ synthase cyclooxygenase active site. Biochemistry 1996; 35: 7330-40.
• 34 Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345 (25) 1809-45.
• 35 Zimmerman N, Kienzle P, Weber AA, Winter J, Gams E, Schrör K, Hohlfeld T. Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 121: 982-4.
• 36 Helgason CM, Tortorice KL, Winkler SR, Penney DW, Schuler JJ, McClelland TJ, Brace LD. Aspirin response and failure in cerebral infarction. Stroke 1993; 24: 345-50.
• 37 Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25: 2331-6.
• 38 Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2 dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-5.
• 39 Vane JR. Cyclo-oxygenase 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120.
• 40 Mitchell JA, Akaarasereenot P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclo-oxygenase. Proc Natl Acad Sci 1993; 90: 11693-7.
• 41 Weber AA, Zimmermann KC, Myerer-Kirchrath J, Schrör K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999; 33: 900.
• 42 Patrignani P, Sciulli MG, Manarini S, Santini G, Cerletti C, Evangelista V. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol 1999; 50: 661-7.
• 43 Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin?. Could it be thromboxane A₂?. Circulation 2002; 105: 1620-2.
• 44 Newman PJ, Derbes RS, Astor RH. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989; 83: 1778-81.
• 45 Sperr WR, Huber K, Roden M, Janisiw M, Lang T, Graf S, Maurer G, Mayr WR, Panzer S. Inherited platelet glycoprotein polymorphisms and a risk for coronary heart disease in young central Europeans. Thromb Res 1998; 90: 117-23.
• 46 Undas A, Brummel K, Musial J, Mann KG, Szczeklik A. PlA2 polymorphism of β₃ integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001; 104: 2666-72.
• 47 Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Barnard MR, Kickler T, Christie DJ, Kundu S, Bray PF. Platelet GP IIIa PlA polymorphisms display different sensitivities to agonists. Circulation 2000; 101: 1013-8.
• 48 Cooke GE, Bray PF, Hamlington JD, Pham DM, Goldschmidt-Clermont PJ. PlA2 polymorphism and efficacy of aspirin. Lancet 1998; 351: 1253.
• 49 Undas A, Sanak M, Musial J. Szczeklik Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet 1999; 353: 982.
• 50 Carter AM, Ossei-Gerning N, Wilson IJ, Grant PJ. Association of the platelet PlA polymorphism of glycoprotein IIb/IIIa and the fibrinogen B13 448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation 1997; 96: 1424-31.
• 51 Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. PlA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997; 349: 385-8.
• 52 Bray PF, Cannon CP, Goldschmidt-Clermont P, Moyé Pfeffer MA, Sacks FM, Braunwald E. The platelet Pl^A2 and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol 2001; 88: 347-52.
• 53 CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
• 54 CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345 (07) 494-502.